Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Theranostic platform for early diagnosis and treatment of cancer based on Acoustofluidics

Project description

Microfluidic platform for cancer vesicle isolation

Extracellular vesicles (EVs) are nano-sized particles released by cells to communicate with their surroundings. Their molecular cargo reflects the state and origin of their parent cells, making EVs highly promising biomarkers for early cancer detection and therapy. However, current EV isolation methods are slow, require large sample volumes and often lack purity, limiting their clinical use. The ERC-funded TheraSonic project tackles this challenge by modelling and developing microfluidic systems to enrich EVs from microlitre quantities of body fluids or tumour-derived samples. These systems aim to deliver high-throughput, scalable and highly selective enrichment of specific EV fractions, laying the foundation for personalised cancer diagnostics and future EV-based therapeutic approaches.

Objective

This proposal develops a pioneering microscale ultrasound-based system to enrich extracellular vesicles (EVs) from µL volumes of whole blood and cancer spheroids, targeting early cancer detection and revolutionizing therapeutic approaches.

EVs, nanoscale particles (30-1000 nm) released by mammalian cells, hold potential as biomarkers for cancer detection and as drug delivery vehicles due to their cell-specific cargo and ability to penetrate cell membranes. However, current isolation methods like centrifugation are time-consuming, require large sample volumes, and lack purity and scalability, limiting clinical application, particularly in high-throughput biomarker discovery and therapeutic development.

I propose to overcome these critical barriers through the creation of TheraSonic, a disruptive acoustic force-based microfluidic platform that leverages a novel particle trapping effect in bulk volumes. TheraSonic will enable the unprecedented enrichment of EVs from µL biofluid samples, offering transformative improvements in purity, scalability, and throughput. By integrating spheroid culturing and multi-omics, this platform will reveal insights into cancer heterogeneity.

Moreover, TheraSonic uniquely enables the selective isolation of EV subpopulations based on size, surface markers, and acoustic properties. This unprecedented resolution will uncover highly specific cancer vesicle profiles that current methods fail to detect, leading to the discovery of highly sensitive and specific cancer biomarkers.

The scalable nature of the platform will be harnessed to significantly increase capacity and throughput, providing needed EV material for novel autologous EV therapies. Combined with organ-on-a-chip technologies, it will facilitate the development of individualised cancer treatments on an unmatched scale.

In summary, TheraSonic represents a disruptive innovation that will induce a paradigm shift in EV enrichment, profoundly impacting cancer research and treatment.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-STG

See all projects funded under this call

Host institution

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Net EU contribution
€ 1 499 726,00
Address
SEMINARSTRASSE 2
69117 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 726,00

Beneficiaries (1)